P-Glycoproteins

Views:
 
Category: Education
     
 

Presentation Description

No description available.

Comments

Presentation Transcript

P-Glycoproteins:

P-Glycoproteins Dr. Mayur M. Maybhate JR II, Dept. of Pharmacology IGGMC, Nagpur.

Slide 2:

Introduction Structure Location and functions Substrates and inhibitors Important interactions Future trends Conclusion

Introduction:

Introduction Transporters are membrane proteins Control the influx of essential nutrients and ions and the efflux of cellular waste, toxins and drugs Controls cellular homeostasis

Slide 4:

Transporters in body ATP binding cassette Solute carrier (ABC) (SLC) ABC-B (1-11) SLC (1-43) ABC-C (1-13) ABC-A (1-12) ABC-B1 (P-glycoprotein)

Transporters and drug responses:

Transporters and drug responses Pharmacokinetic – Absorption, metabolism, excretion of drugs

Slide 6:

Pharmacodynamics – Target for many drugs e.g. SSRIs, TCAs

Mechanism of membrane transport:

Mechanism of membrane transport

P-Glycoprotein:

P-Glycoprotein Most important member of ABC family Transmembrane protein coded by MDR-1 gene Functions to actively pump a diverse array of xenobiotics out of the cells in which it is expressed

Historical aspects:

Historical aspects First described in 1976, by JULIANO & LING in Chinese hamster ovary cells selected in culture for colchicines resistance PULLIAM et al. in 1985 discovered the particular increased penetration of ivermectin through the BBB resulting in 31-fold higher concentration of the drug in the brain than in the plasma in MDR knocked out mice

Slide 10:

MICKISCH et al., 1991, found P-glycoprotein inhibition due to cyclosporine enhanced paclitaxel (Taxol) oral bioavailability

Structure:

Structure Single polypeptide Two homologous halves Each contains six transmembrane domains and a hydrophilic region with an ATP-binding domain

Locations and function:

Locations and function 1) Epithelial cells of gastrointestinal tract Influx of essential nutrients and ions and efflux of cellular waste , drugs etc. Extensive overlap in the substrate specificities and tissue localization of P- gp and drug metabolizing enzyme in the cytochrome P450 (CYP3A4)

Slide 13:

Lead to the hypothesis that these two proteins work together to protect the body from absorption of harmful xenobiotics, acting synergistically in the small intestine

Slide 15:

2) Hepatocytes in liver Even if drug is absorbed it is expelled into bile, enters intestine again Work synergistically with CYP3A4 in liver

Slide 16:

3) Renal epithelial cells Efflux of drugs into tubular lumen, easily excreted

Slide 17:

4) Tissues with barrier function Blood brain Blood testis Blood placenta limiting entry and accumulation of many drugs into the brain and contributing to the protective function of the central nervous system

Slide 18:

5) Cancer cells Highly expressed, leading to efflux of anticancer agents from cells Resistance to these agents

Substrates and inhibitors:

Substrates and inhibitors Various classes of drugs Resulting in efflux of drug from body, lowering their plasma concentration

Important interactions:

Important interactions P- gp induction or inhibition may have a substantial effect on the pharmacokinetics and pharmacodynamics of concomitantly administered drugs that are substrates for this transporter.

Slide 22:

Digoxin Absorption reduced due to co-administration of rifampicin (MDR1 inducer) Renal excretion retarded due to concurrent administration of MDR1 inhibitors (verapamil, quinidine etc.)

Slide 23:

Loperamide Peripheral opioid for diarrhea, substrate for P-glycoprotein Co-administration of quinidine has caused marked respiratory depression

Slide 24:

Protease inhibitors Ritonavir , Nelfinavir , Indinavir , Saquinavir substrates for P-glycoprotein P- gp transport at the intestinal and/or hepatic level limits the systemic bioavailability Poor penetration into the brain, testis Treatment ineffective and development of resistance faster

Slide 25:

Anticancer agents MDR1 highly expressed in cancer cells, rendering resistant to anticancer agents Reduced bioavailability Paclitaxel, actinomycin D, vincristine etc. substrates for P- gp .

Future trends:

Future trends P- gp induction does not have a therapeutic role till date , P- gp inhibition is an attractive therapeutic approach to reverse multidrug resistance

Anticancer therapy:

Anticancer therapy Strategies to modulate P- gp function are being pursued actively in oncology reversal of multidrug resistance in tumours several newly developed agents that inhibit P- gp function are in phase I-III clinical trials. e.g. ONT 093 PSC 31665

Antiretroviral therapy:

Antiretroviral therapy Blockage of P- gp may be useful in facilitating greater intestinal absorption, bioavailability and penetration of protease inhibitors into HIV sanctuary sites as well as reduced excretion. Simplify protease inhibitor-containing regimens by reducing the oral doses of protease inhibitors and the frequency at which they are taken

Links with diseases:

Links with diseases MDR1 gene polymorphisms increases susceptibility to diseases such as Parkinson's disease, inflammatory bowel disease, multi-drug resistant epilepsy and renal carcinoma. MDR1 induction beneficial ???

Conclusion:

Conclusion P-glycoprotein encoded by MDR1 gene that influences drug pharmacokinetic and Pharmacodynamics P- gp inhibition is an attractive therapeutic approach to reverse multidrug resistance

References:

References Kathleen M. Giacomini and Yuichi Sugiyama membrane transporters and drug response ; Goodman and Gilman's , Pharmacological basis of therapeutics;11;40-65;2005. Bertram G. Katzung , Introduction, Basic and clinical pharmacology:11:9-10;2009

Slide 33:

BRADY, J.M. et al., Tissue distribution and chemical induction of multiple drug resistance genes in rats; Drug Metabolism and Disposition , Baltimore; vol.30; 7; 2005. CUMMINS, C. L. et al. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: Studies using the rat single-pass intestinal perfusion model; Journal of Pharmacology and Experimental Therapeutics , Baltimore; v.305, n.1; p.306-314; 2006.

Slide 34:

FROMM, M.F. Importance of P-glycoprotein at blood-tissue barriers; TRENDS in Pharmacological Sciences ; v.25; n.8; p.423-429; 2004. KHARASCH, E.D. et al. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. British Journal of Clinical Pharmacology , Oxford, v.57; n.5; p.600-610, 2003.

Slide 35:

THANK YOU

authorStream Live Help